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AbstrAct
Objectives This study aims to summarise the evidence on 
more than 140 pharmacological and non-pharmacological 
treatment options for major depressive disorder (MDD) and 
to evaluate the confidence that patients and clinicians can 
have in the underlying science about their effects.
Design This is a review of systematic reviews.
Data sources This study used MEDLINE, Embase, 
Cochrane Library, PsycINFO and Epistemonikos from 2011 
up to February 2017 for systematic reviews of randomised 
controlled trials in adult patients with acute-phase MDD.
Methods We dually reviewed abstracts and full-text 
articles, rated the risk of bias of eligible systematic reviews 
and graded the strength of evidence.
Results Nineteen systematic reviews provided data on 28 
comparisons of interest. For general efficacy, only second-
generation antidepressants were supported with high 
strength evidence, presenting small beneficial treatment 
effects (standardised mean difference: −0.35; 95% CI 
−0.31 to −0.38), and a statistically significantly higher 
rate of discontinuation because of adverse events than 
patients on placebo (relative risk (RR) 1.88; 95% CI 1.0 
to 3.28). Only cognitive behavioural therapy is supported 
by reliable evidence (moderate strength of evidence) 
to produce responses to treatment similar to those of 
second-generation antidepressants (45.5% vs 44.2%; RR 
1.10; 95% CI 0.93 to 1.30). All remaining comparisons of 
non-pharmacological treatments with second-generation 
antidepressants either led to inconclusive results or 
had substantial methodological shortcomings (low or 
insufficient strength of evidence).
Conclusions In contrast to pharmacological treatments, 
the majority of non-pharmacological interventions for 
treating patients with MDD are not evidence based. For 
patients with strong preferences against pharmacological 
treatments, clinicians should focus on therapies that have 
been compared directly with antidepressants.
Trial registration number International Prospective 
Register of Systematic Reviews (PROSPERO) registration 
number: 42016035580.
IntroductIon
Major depressive disorder (MDD)1 is the most 
prevalent and disabling form of depression, 
affecting more than 30 million Europeans 
per year.2 In the USA, the estimated lifetime 
prevalence of MDD is 16%.3 In addition to 
its burden of disease, MDD exerts a negative 
impact on physical health4–7 and adherence 
to medical treatment.8 9
Second-generation antidepressants (eg, 
selective serotonin reuptake inhibitors or 
selective serotonin norepinephrine reuptake 
inhibitors) are the most commonly used treat-
ments for acute MDD.10 Most evidence-based 
guidelines recommend these medications as 
a first-step therapy.11 12
Nevertheless, patients with depression may 
prefer non-pharmacological options because 
antidepressant therapies also come with 
considerable risks for harms. Up to 63% of 
patients on second-generation antidepres-
sants experience adverse events; between 7% 
and 15% of patients discontinue treatment 
because of adverse events.13 Concerns about 
the ‘addictiveness’ of antidepressants are also 
a common reason for patients’ scepticism 
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Strengths and limitations of this study
 ► This is the first review of systematic reviews 
assessing the benefits and harms of more than 
140 pharmacological and non-pharmacological 
treatments for major depressive disorder.
 ► We used rigorous systematic review and novel 
graphical methods to summarise treatment effects 
and present the strength of the underlying evidence.
 ► Like any review of systematic reviews, we could 
draw conclusions only about interventions that had 
been assessed by systematic reviews.
 ► We did not take combination or augmentation 
strategies of antidepressants with non-
pharmacological interventions into consideration, 
but in clinical practice, this is a common treatment 
strategy.
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about prescription medications14 15; women and ethnic 
minorities, in particular, often prefer non-pharmaco-
logical options as first-step treatments of depression.16 17 
Antidepressants also have a substantially higher treat-
ment-specific stigma than, for example, herbal remedies.18
Such scepticism toward antidepressants reflects a 
general trend toward ‘natural treatments’ throughout 
medicine. In 2012, an estimated 59 million persons in 
the USA spent US$30.2 billion in out-of-pocket expenses 
on some type of complementary health approach.19 In a 
survey of psychiatric patients, more than half of patients 
with self-reported depressive disorders used complemen-
tary and alternative medicine (CAM) therapies.20
Non-pharmacological treatment options for depression 
are vast. The Cochrane Depression and Neurosis Group 
lists 87 psychological interventions21; a comprehensive 
summary from an Australian patient advocacy group 
catalogued 56 CAM interventions for the treatment of 
depression (beyondblue: A guide to what works for depres-
sion (http:// resources. beyondblue. org. au/ prism/ file? 
token= BL/ 0556)).
Because of the multitude of non-pharmacological 
options, for clinicians, the great challenge is how to 
balance patients’ interest in alternatives to medications 
with the professional responsibility to choose treatments 
that are supported by scientific evidence.
The goal of this project was to provide an overview of 
the general efficacy and risk of harms of pharmacolog-
ical and non-pharmacological interventions for treating 
patients with MDD. Furthermore, we strove to compare 
benefits and harms of non-pharmacological interven-
tions with second-generation antidepressants as the most 
common treatments for acute-phase MDD.
Methods
A review of systematic reviews is designed to compile 
evidence from multiple systematic reviews of inter-
ventions into one accessible, usable document.22 We 
registered the protocol in PROSPERO (International 
Prospective Register of Systematic Reviews; registration 
number: 42016035580). 
Populations, interventions, comparators, outcomes, timing 
and settings
table 1 presents eligibility criteria for populations, inter-
ventions, comparators, outcomes, timing and settings 
of systematic reviews and meta-analyses. In this table, 
the term ‘articles’ refers to any systematic reviews or 
meta-analyses of randomised controlled trials (RCTs) 
published in peer-reviewed journals or other sources. We 
limited the publication period to 2011 or later because 
methods research indicates that more than 50% of system-
atic reviews are outdated 5.5 years after publication.23
For eligible psychological interventions, we used the 
Cochrane Depression and Neurosis Group classification.21 
For CAM, we were interested in any intervention that 
the non-profit patient advocacy group beyondblue listed 
as a ‘non-medical’ intervention for treating depressed 
patients.24 Online supplementary file 1 lists the 87 eligible 
psychological interventions and the 56 eligible CAM 
interventions.
Literature searches
To identify relevant systematic reviews or meta-analyses, 
we searched MEDLINE (via PubMed), Embase, the 
Cochrane Library, PsycINFO and Epistemonikos. We 
used both index terms (eg, Medical Subject Headings, 
Emtree) and free-text keywords to search for MDD. We 
limited the electronic searches to ‘human,’ ‘English, 
German or Italian language,’ ‘adults’ and systematic 
reviews or meta-analyses. We searched sources from 1 
January 2011 to 20 February 2017.
We imported all citations into an electronic database 
(EndNote X.6.0.1). The search strategies and yields of 
the searches are given in online supplementary file 2.
screening process
We developed and pilot-tested review forms using the 
eligibility criteria in table 1. In a two-stage review process, 
two persons independently reviewed abstracts and full-
text articles. We resolved discrepancies by consensus or by 
consulting a third senior investigator. For each compar-
ison and outcome, we chose a single systematic review 
providing the best available evidence. If more than one 
systematic review on the same intervention met eligibility 
criteria, we chose the review with (1) the lowest risk of 
bias, (2) the most recent search date and (3) the most 
comprehensive scope. For each eligible systematic review, 
we determined whether RCTs included in it also met our 
inclusion criteria (see table 1).
data abstraction
We designed and used a structured form to ensure consis-
tency of data abstraction. If all studies in a systematic 
review met our eligibility criteria, we extracted summary 
estimates from meta-analyses. If one or more studies did 
not meet our eligibility criteria, we extracted data from 
individual studies. For example, when systematic reviews 
included mixed populations with different depressive 
disorders, we retrieved individual publications on patients 
with MDD. When data were unclear or contradictory, 
we contacted review authors for clarification. A second 
senior reviewer evaluated the completeness and accuracy 
of the data abstraction.
risk of bias assessment
To assess methodological limitations (risk of bias) 
of eligible systematic reviews, we used the AMSTAR 
(Assessing Methodological quality of Systematic Reviews) 
tool.25 Two independent reviewers assigned ratings for 
study limitations. They resolved any disagreements by 
consensus or by consulting a third independent party. For 
the risk of bias of individual studies in a systematic review, 
we relied on the ratings of the original reviews’ authors. 
AMSTAR ratings of included studies are given in online 
supplementary file 3.
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evidence synthesis
Our aim was to depict the magnitude of beneficial 
and harmful treatment effects and the confidence that 
patients and clinicians can have in the underlying science 
about these effects. We used effect estimates of systematic 
reviews if all included RCTs met our eligibility criteria. 
In instances where individual RCTs of eligible systematic 
reviews did not meet our eligibility criteria (eg, because 
they used treatment as usual as a control group), we recal-
culated quantitative analyses removing ineligible studies.
For general efficacy, we were interested in the improve-
ment of depressive symptoms. We present standardised 
mean differences because methods of assessments 
differed substantially across systematic reviews. A 
Table 1 Study eligibility criteria: populations, interventions, comparators, outcomes, timing and settings for the review of 
reviews (PICOTS)
PICOTS Specific inclusion or exclusion criteria
Population Adult (18 years and above) patients of all races and ethnicities with MDD who are undergoing first-step 
treatment during acute treatment phase.
We did not include populations with bipolar disorder, perinatal depression, dysthymia, seasonal affective 
disorder or subsyndromal depression. We also did not include populations exclusively comprising patients 
with medical comorbidities and depression (eg, populations with heart disease and depression or with 
cancer and depression)
Interventions Eligible interventions had to be used as an initial monotherapy for acute-phase MDD
Psychological and behavioural interventions
•Behaviour therapy/behaviour modification
•Cognitive behavioural therapy
•Third wave cognitive behavioural therapies
•Psychodynamic therapies
•Humanistic therapies
•Integrative therapies
•Systemic therapies
•Other psychologically oriented interventions
Somatic treatments
•Any physical exercise
•Light therapy
•Tai Chi/Qigong
•Yoga
CAM therapies
•Dietary supplements (eg, S-adenosyl-L-methionine (SAMe), omega-3 fatty acids)
•Herbal remedies (eg, St John’s wort, Chinese herbal formulations)
•Other CAM therapies used for the treatment of depression (eg, acupuncture)
Pharmacological interventions
•Second-generation antidepressants
•Tricyclic antidepressants
•Off-label pharmacological treatments
We did not include combination treatments
Comparators •Any inactive intervention (eg, placebo, waiting list, sham acupuncture, no care)
•Second-generation antidepressants (agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, 
fluoxetine, escitalopram, fluvoxamine, levomilnacipran, mirtazapine, nefazodone, paroxetine, sertraline, 
trazodone, venlafaxine, vilazodone, vortioxetine)
We did not include treatment as usual as a comparator because it is not standardised and cannot be 
considered an inactive intervention.
Outcomes Efficacy and effectiveness: response, change of depression scores
Adverse events (safety and tolerability): overall discontinuation, discontinuation because of adverse events
Timing No restrictions
Setting All settings
Time period Articles published in 2011 and later
Study design Systematic reviews* and meta-analyses (if based on a systematic review) of RCTs published in English, 
German or Italian languages
*Systematic reviews are defined based on the Cochrane handbook as a literature review that attempts to collate all empirical evidence 
using (a) clearly stated objectives and predefined eligibility criteria, (b) an explicit reproducible methodology, (c) a systematic search, (d) an 
assessment of the validity of the findings of the included studies and (e) a systematic presentation, and synthesis, of the characteristics and 
findings of the included studies.22
CAM, complementary and alternative medicine; MDD, major depressive disorder; RCT, randomised controlled trial.
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standardised mean difference of 0 indicates that both 
groups had similar improvements; effects of −0.5 or −1 
indicate that 69% or 84% of patients in the intervention 
group, respectively, had greater reductions on depression 
scores than the average patient in the control group. For 
the risk of harms, we present overall discontinuation rates 
and discontinuation rates because of adverse events.
For the comparative efficacy of non-pharmacolog-
ical treatments with second-generation antidepressants, 
we used relative risk (RR) of response to treatment (as 
defined by the authors but most commonly presented 
as a 50% reduction of symptoms on a depression rating 
scale). If necessary, we recalculated RR so that a value 
below 1 would represent fewer responses of patients using 
non-pharmacological treatments and a value greater than 
1 would represent more responses. We present treatment 
effects also as absolute risk reductions or increases (differ-
ences in numbers of patients who respond to treatment, 
per 1000 treated patients) with the related 95% CIs.
Quantitative analyses
As described above, in instances where individual RCTs 
of eligible systematic reviews did not meet our eligibility 
criteria, we recalculated quantitative analyses removing 
ineligible studies. To summarise data quantitatively, we 
followed established guidance.26 For all analyses, we 
used both random-effects and fixed-effects models. We 
report results of random-effects analyses (DerSimonian & 
Laird). In general, the findings from the random-effects 
and fixed-effects analyses were similar. We assessed statis-
tical heterogeneity between studies by calculating the 
χ2 statistic and Cochran’s q. We used the I2 statistic (the 
proportion of variation in study estimates attributable to 
heterogeneity) to estimate the magnitude of heteroge-
neity. We examined potential sources of heterogeneity 
using sensitivity analyses and assessed publication bias 
with funnel plots and Kendall’s tests.
For general efficacy, we estimated standardised mean 
differences using Hedges’ g.27 If systematic reviews 
presented effect sizes as Cohen’s d, we used a correction 
factor (J) to convert to Hedges’ g: ( J = 1− 34df−1), where 
df stands for ‘degrees of freedom’.
If systematic reviews presented effect estimates of 
general efficacy as dichotomous outcomes, we calcu-
lated log ORs and converted them first to Cohen’s d 
(d = logOR
√
3
pi ) and then to Hedges’ g using the correc-
tion factor presented above. For each estimate, we 
calculated variances and CIs.
For all statistical calculations, we used Microsoft Excel 
(V.2010, Microsoft, Redmond, WA, USA) or Review 
Manager 5.3 (V.5.3. Copenhagen, The Cochrane Collab-
oration, 2014).
strength of the evidence
We graded the strength of evidence based on guidance 
for AHRQ Evidence-based Practice Centres on the use 
of GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) Working Group.28 29 
Strength of evidence can take four grades: high, moderate, 
low or insufficient. We considered grades of high or 
moderate strength as reliable evidence.
resuLts
Searches detected 2532 citations; 19 systematic reviews 
met our eligibility criteria and provided the most recent 
summaries of evidence on 28 comparisons of interest.30–44 
Thirty-one additional systematic reviews formally met eligi-
bility criteria, but their content was superseded by at least 
one of the 19 reviews mentioned above (online supple-
mentary file 4). figure 1 presents the flow of the literature; 
table 2 presents characteristics of included reviews.
For the majority of non-pharmacological treatments, 
we did not find any systematically appraised evidence.
In the following sections, we first provide an overview of 
treatment effects of non-pharmacological and common 
pharmacological treatments compared with inactive inter-
ventions.
We then present results on the comparative benefits 
and harms of non-pharmacological interventions and 
second-generation antidepressants.
non-pharmacological and pharmacological treatments 
compared with inactive interventions
Benefits of treatments
Sixteen systematic reviews provided data on 17 compar-
isons with inactive interventions (placebo, sham 
interventions or waiting list).30–32 35–37 39–43 45–50 figure 2 
provides an overview of treatment effects of non-pharma-
cological and common pharmacological treatments for 
MDD when compared with inactive interventions using 
standardised mean differences. The four commonly used 
pharmacological interventions in the figure are agomela-
tine, alprazolam, second-generation antidepressants and 
tricyclic antidepressants.
The comparisons in the figure are ordered by the 
strength of evidence grades and then alphabetically by 
the name of the intervention. figure 2 also presents the 
numbers of trials and the total number of subjects in those 
trials; thus, the size of the circles reflects the numbers of 
participants (on a logarithmic scale). Online  supplemen-
tary file 5 provides detailed strength of evidence ratings.
The only treatments for acute-phase MDD with high 
strength of evidence were second-generation antide-
pressants (figure 2). Within this class, the medications 
rendered modest treatment effects (−0.35; 95% CI −0.31 
to −0.38). Although the dataset included 24 unpublished 
studies,44 treatment effects might still be inflated because 
several methods studies indicate that publication bias is a 
serious problem in this drug class.51 52
Reviews on some psychological interventions (third 
wave cognitive behavioural therapy (CBT) and psychody-
namic therapies) reported large treatment effects (third 
wave CBT: −0.97; 95% CI −0.6 to −1.34; psychodynamic 
therapies: −2.02; 95% CI −0.9 to −3.14; low or insufficient 
strength of evidence, respectively; figure 2). Studies of 
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these two psychological interventions used waiting lists as 
control interventions. Patients on waiting lists usually do 
not experience beneficial placebo effects, which can lead 
to artificially large treatment effects when active inter-
ventions are compared with waiting list controls. Placebo 
effects in psychiatric populations can be substantial; for 
example, on average, 35%–40% of patients in double-
blinded trials of antidepressants achieved a response 
(usually defined as a 50% reduction of symptoms) to 
placebo treatment.53
For many of the therapies in figure 2, the types of 
inactive comparators varied and involved different magni-
tudes of placebo effects. Consequently, comparisons of 
treatment effects across different interventions have to be 
made cautiously.
Risk of harms
Information on overall discontinuation and discontin-
uation because of adverse events was scarce. figure 3 
depicts the absolute risk reductions or increases for 
overall discontinuation and discontinuation because of 
adverse events—namely, the bars showing the 95% CIs of 
either fewer or more discontinuations per 1000 patients. 
Only patients on second-generation antidepressants had 
a statistically significantly higher rate of discontinuation 
because of adverse events than patients on placebo (4.5% 
vs 2.6%; RR 1.88, 95% CI 1.07 to 3.28). Most compar-
isons were of low or insufficient strength of evidence, 
indicating little certainty in the available effect estimates 
(details in  online supplementary file 5).
non-pharmacological treatments compared with  
second-generation antidepressants
Three systematic reviews provided data on response to 
treatment for 11 non-pharmacological interventions 
(four psychological, six CAM and exercise) compared 
with second-generation antidepressants for the treatment 
of acute-phase MDD.30 31 44 We used response to treatment 
as defined by authors of the reviews; in most cases, this 
was a 50% reduction of symptoms as measured on a 
depression rating scale (eg, Hamilton Depression Rating 
Scale). figure 4 depicts the absolute risk reductions or 
increases for response to treatment per 1000 patients. As 
in the other figures, the comparisons are ordered by the 
strength of evidence grades and then alphabetically by 
the name of the intervention. These estimates are based 
Figure 1 Flow diagram of review of systematic reviews of treatments for major depressive disorder in adults.
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on meta-analyses or, if meta-analyses were not feasible, 
on results from the largest and most reliable trial. Online 
supplementary file 5 provides detailed information on 
our ratings of strength of evidence domains.
Psychological interventions
One systematic review reported on the efficacy of four 
psychological treatments relative to second-generation 
antidepressants (figure 4); these included CBT, integra-
tive therapies, psychodynamic therapies and third wave 
CBT.44 The most reliable evidence (moderate strength of 
evidence) compared CBT with second-generation antide-
pressants. A meta-analysis of five RCTs of low or medium 
risk of bias with 660 patients provided consistent evidence 
that the two options had similar efficacy (45.5% vs 44.2%; 
RR 1.10; 95% CI 0.93 to 1.30).54 Including three high risk 
of bias studies yielded similar results (RR 0.98; 95% CI 0.80 
to 1.20).54
Integrative therapies also had response rates 
similar to those for antidepressants (low strength of 
evidence).44 Patients treated with third wave CBT had 
significantly higher response rates than those on antide-
pressants, but the strength of evidence was insufficient 
because of the small sample size and under-dosing of 
antidepressants in the available trial. No evidence on 
response was available for psychodynamic therapies, but 
the available evidence indicated remission rates similar to 
those for second-generation antidepressants.44
CAM interventions
Three systematic reviews reported on comparisons with 
second-generation antidepressants for seven (of 56 
Figure 2 Overview of the strength of evidence of non-pharmacological and pharmacological interventions compared 
with inactive interventions for the treatment of adult major depressive disorder. CBT, cognitive behavioural therapy; SAMe, 
S-adenosyl-L-methionine; SGA, second-generation antidepressants; SMD, standardised mean difference; TCA, tricyclic 
antidepressants.
Figure 3 Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events 
comparing non-pharmacological interventions with inactive interventions. CBT, cognitive behavioural therapy; SAMe, 
S-adenosyl-L-methionine; SGA, second-generation antidepressants; TCA, tricyclic antidepressants.
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eligible) CAM interventions—namely, acupuncture, 
Chinese herbal medicine (without Gan Mai Da Zao), Gan 
Mai Da Zao, omega-3 fatty acids, S-adenosyl-L-methionine 
(SAMe), St John’s wort and saffron (figure 4).30 31 44 Except 
for omega-3 fatty acids, none of the comparisons yielded 
statistically significant differences. Based on results of 
a network meta-analysis, patients using omega-3 fatty 
acids were statistically significantly less likely to achieve 
response than patients on antidepressants (RR 0.51; 
95% CI 0.33 to 0.79).44 The reliability of results involving 
CAM interventions, however, is low. Therefore, the lack of 
statistical significance of most comparisons should not be 
interpreted as equivalence of treatment effects.
Some comparisons had wide CIs (eg, acupuncture, 
Gan Mai Da Zao, SAMe, saffron) rendering inconclusive 
findings about the comparative efficacy of treatments. 
Other comparisons had more precise results (eg, Chinese 
herbal medicine or St John’s wort) but severe method-
ological shortcomings. For example, several trials of St 
John’s wort used moderate-dose or low-dose second-gen-
eration antidepressant regimens as comparators, not fully 
using the approved range of antidepressant doses.44 Two 
of five trials comparing Chinese herbal medicine with 
antidepressants had serious design or analytic limita-
tions such as flawed randomisation or lack of allocation 
concealment.30
Exercise
A network meta-analysis produced inconclusive results 
about differences in response rates between physical exer-
cise and second-generation antidepressants (figure 4).44
Comparative harms
The discontinuation of treatment because of adverse 
events were generally lower for patients treated with 
non-pharmacological interventions than for those 
receiving second-generation antidepressants, although 
differences did not always reach statistical significance. 
Patients on St John’s wort had a statistically significantly 
lower rate of discontinuation because of adverse events 
(3.8% vs 6.8%; RR 0.59; 95% CI 0.38 to 0.89).44 Patients 
on any psychological treatment had a numerically lower 
risk for discontinuation of treatment because of adverse 
events (2.1% vs 7.1%; RR 0.37; 95% CI 0.12 to 1.12).44 Like-
wise, patients who used physical exercise discontinued 
treatment because of adverse events less often than those 
treated with antidepressants (0% vs 6%; RR 0.15; 95% CI 
0.01 to 2.86), but the difference did not reach statistical 
significance.44 Little evidence on treatment discontinua-
tion was available for most CAM interventions, particularly 
for Chinese herbal medicine or saffron.30 31
dIscussIon
Out of more than 140 interventions of interest, our 
review identified only five treatments for which the 
general efficacy for acute-phase MDD is supported by reli-
able evidence (ie, evidence graded as high or moderate 
strength of evidence). Among those, CBT is the only 
psychological intervention and St John’s wort is the only 
CAM intervention. For the vast majority of non-phar-
macological interventions, either no systematic review 
evidence was available or the certainty of the evidence 
was severely limited. When compared with second-gen-
eration antidepressants, only CBT had similar efficacy 
based on moderate strength evidence. Overall, our anal-
yses highlighted a lack of robust evidence for the majority 
of non-pharmacological treatments.
To our knowledge, our study was the first review of 
systematic reviews assessing more than 140 interven-
tions for treating adults with MDD. It provides a unique 
synthesis of the available, systematically appraised 
evidence on these treatment options, beyond the indi-
vidual reviews on depression therapies that have been 
published over the past decade.
Our study does have several limitations, however. First and 
most importantly, like any review of systematic reviews, we 
could draw conclusions only about interventions that had 
been assessed by systematic reviews. Conceivably, RCTs are 
available for some interventions that have never been eval-
uated systematically in a review. Therefore, the absence of 
systematic reviews cannot be equated with an absence of 
RCTs. In addition, eligibility criteria of these reviews some-
times included only a subset of available studies (eg, studies 
conducted in primary care settings). Such reviews do not 
provide a picture of the totality of the evidence but sometimes 
Figure 4 Absolute risk reductions or increases of response to treatment comparing non-pharmacological interventions with 
second-generation antidepressants for the treatment of adult major depressive disorder. 1Number of participants in trials 
that directly compared intervention with second-generation antidepressants. 2Number of trials in network meta-analysis that 
contributed to the effect estimate. CBT, cognitive behavioural therapy; RR, relative risk; SAMe, S-adenosyl-L-methionine; SGA, 
second-generation antidepressants.
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were the only ones that were available on a specific compar-
ison of interest. Second, reviews of systematic reviews rely 
on results from other investigators. Although most of the 
reviews had few problems in methods, conceivably these 
authors did miss some RCTs. Likewise, we relied on the risk 
of bias appraisals of RCTs that authors of included system-
atic reviews had done. Most reviews used two independent 
reviewers to rate risk of bias; double checking their ratings 
was beyond the scope of our study. Third, reporting of char-
acteristics of populations, interventions, comparators and 
outcomes in included systematic reviews was often subop-
timal. Frequently, we could not tell with certainty whether 
included populations were exclusively adult patients with 
acute-phase MDD; sometimes, we could not determine the 
exact control interventions that authors had combined in 
their meta-analyses. We did not take several meta-analyses 
into consideration that combined studies with inactive 
treatments and treatment as usual as control interventions. 
Because treatment as usual cannot be viewed as ‘inactive,’ 
we believe that such meta-analyses will lead to biased results. 
Fourth, as in any literature review, the reliability of our 
results is directly related to number of available studies and 
their quality. Some of the systematic reviews included only 
few studies with few events. The strength of evidence grades 
reflect these concerns and the certainty of our results; for 
most cases, these grades were low or insufficient. Such low 
strength of evidence indicates that future studies might 
have a substantial impact on the effect estimates reported 
in our review. Furthermore, we had no way to assess how 
meta-biases such as reporting biases or funding biases could 
have affected our findings. Finally, we did not take combi-
nation or augmentation strategies of antidepressants with 
non-pharmacological interventions into consideration, but 
in clinical practice, this is a common treatment strategy.
We believe that our results may have important clinical 
implications. They provide patients and clinicians with 
solid and up-to-date information about which treatment 
options have (or have not) been evaluated in rigorous 
systematic reviews. For patients with strong preferences 
against pharmacological treatment, clinicians can offer 
therapies that have been compared directly with antide-
pressants. CBT, for example, is a well-supported, first-step 
alternative to pharmacological treatment of MDD. Other 
psychological or CAM interventions might be equally 
effective, or nearly so, but the evidence base is less 
reliable. The majority of psychological and CAM inter-
ventions, however, are not evidence based; given better 
alternatives, clinicians should probably advise against 
them. Such shared and informed decision making might 
enhance treatment adherence55 and could ultimately 
improve treatment outcomes for patients with MDD. This 
is especially important because treatment continuity is 
one of the main challenges in treating such patients.56
Our findings also highlight key areas of future research 
needs. Subsequent trials need to address gaps in our 
current knowledge about the efficacy of non-pharmaco-
logical interventions and about the comparative benefits 
and harms of pharmacological and non-pharmacological 
treatments for MDD. In particular, major research gaps 
pertain to information about the comparative risk of 
harms and patient-relevant outcomes such as functional 
capacity and quality of life. For patients and clinicians alike, 
balancing benefits and harms based on objective informa-
tion is crucial. Lack of information about harms can lead 
to a biassed knowledge base and the potential for decisions 
that cause more harm than good. Future studies should 
assess benefits and harms with standardised measures to 
allow for more direct comparisons across studies.
In the end, even in the absence of clearly informative 
evidence, clinicians and patients need to make decisions. 
They can discuss what is known and what is not known about 
the available options to treat MDD, and our work provides 
a way to start those conversations. For patients with strong 
preferences against pharmacological treatments, clinicians 
should focus on therapies that have been compared directly 
with antidepressants. This review provides a framework to 
guide discussion of the potential options.
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